Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by SMlachakeon Jul 23, 2022 3:31pm
189 Views
Post# 34845673

RE:RE:RE:around TWO DOLLAR TARGET

RE:RE:RE:around TWO DOLLAR TARGET After quite a bit of DD, I think your range is quite realistic. A bid at 5 and maybe a deal at 5-7. It's still too early for anything beyond that. The potential is there but time is needed. SAMI took almost 2years to land a deal. And while we can't say it is not making money (unless anyone knows how much the deal is worth), we can see how slow the market is to respond. A deal after a long trial by a big provider is definitely a good indicator that the technology will earn, but time is a factor. I would be happy with 5 before End year, 10.. maybe by mid-end 2023. That is a X10 at these prices, can't say no to that.
<< Previous
Bullboard Posts
Next >>